{"id":"https://genegraph.clinicalgenome.org/r/0204e276-fa45-4756-a380-eb494f5237f8v1.0","type":"EvidenceStrengthAssertion","dc:description":"STAT3 was first reported in relation to early-onset multisystem autoimmune disease in 2014 (PMID: 25038750). STAT3 gain-of-function (GOF) variants are associated with lymphoproliferation, autoimmunity and hypogammaglobulinemia. There is a wide array of clinical symptoms observed and is hypothesized to be due to differences in the variantâ€™s location in functional domains of STAT3 (PMID: 31770611). Some STAT3 GOF mutations exhibit incomplete penetrance in the population, suggesting that STAT3 GOF mutations alone are not enough to cause disease in some cases. Over 49 variants have been reported in the literature (PMID: 34366294). For this curation, 10 variants in 10 probands in 3 publications (PMIDs: 25359994, 25349174, 25038750) are included. The maximum score for genetic evidence (12 pts.) was reached in this curation and no further variants are included.\n\nThis gene-disease association is also supported by expression studies, functional assays, and animal models. STAT3 is important in cytokine and growth factor signaling. STAT3 is phosphorylated by receptor associated Janus kinases (JAK), causing formation of STAT homo- or heterodimers, followed by translocation into the nucleus to act as a transcription factor. STAT3 is widely expressed and is important for many processes in immunity, cell growth and apoptosis. The exact mechanism leading to STAT3 GOF disease is unknown due to the wide array of functions STAT3 can perform. However, there is evidence STAT3 GOF variants impact immune cell function, leading to autoimmunity. STAT3 GOF variants lead to higher levels of functional STAT3 in patient cells (PMID: 25359994), and lead to increases in negative regulators of cytokine signaling, suggesting over-activity of immune cells (PMID: 25359994). Supporting this finding, groups have shown increased differentiation of T helper 17 cells (TH17) in STAT3 GOF patients (PMID: 26343524), a cell type that is implicated in mediating many autoimmune diseases. Lastly, the generation of a mouse model substituting a STAT3 patient variant led to increased incidence of diabetes mediated by CD8 T cells (PMID: 34115115), as identified in a subset of STAT3 GOF patients. Altogether, published evidence suggests the STAT3 GOF variants are leading to immune cells with increased reactivity and likelihood to cause autoimmunity. However, more mechanistic studies are needed to fully understand the range of clinical symptoms seen in patients.\n\nOf note, somatic STAT3 GOF mutations have been identified in cases of large granulocytic leukemia (LGL) (PMIDs: 23207521, 22591296) and likely represent a pathogenic driver of this process. There have been reports of individuals with germline STAT3 GOF developing LGL, though the prevalence of LGL cases caused by germline STAT3 GOF variants is unknown. Future review of this curation will need to assess the relationship between LGL and germline STAT3 GOF variants as more research is performed.\n\nIn summary, STAT3 is definitively associated with early-onset multisystem autoimmune disease and immune deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on January 20, 2022 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0204e276-fa45-4756-a380-eb494f5237f8","GCISnapshot":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2022-02-16T18:17:31.945Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2022-02-16T18:17:12.967Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf75b375-c9ff-4f8b-a159-40537f731788","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a719dcc2-1aa8-4395-9957-d30b557fb41a","type":"Finding","dc:description":"In humans, this STAT3 GOF variant is associated with early incidence of type I diabetes. In the NOD mouse model, mice start to become diabetic between 10-15 weeks of age. With the addition of the human STAT3 variant, the mice start became diabetic at 5-10 weeks of age. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34115115","rdfs:label":"Stat3-K392R mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fbdc67d1-16f5-4e8d-8637-986cddcd8b40","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b7a0eefa-067e-47d7-992a-4344fdc8ece7","type":"FunctionalAlteration","dc:description":"SOCS3 mRNA was measured in healthy controls and compared to patient cells. SOCS3 is an important regulator of cytokine signaling, and has been shown to regulate STAT3 signaling. As such, it is positively correlated with STAT3 signaling. In this experiment, SOCS3 was significantly unregulated following IL-21 stimulation when compared to healthy control samples, suggesting over-active STAT3.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","rdfs:label":"SOCS3 measurement"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/137ab257-96c7-4c1a-9c5a-63a47b6b054e","type":"EvidenceLine","dc:description":"strong experimental evidence with multiple variants shown","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dee641ad-d3bd-4807-959e-87fcaf6e2e96","type":"FunctionalAlteration","dc:description":"Increased STAT3 reporter activity when variants were present","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33501615","rdfs:label":"STAT3 GOF luciferase"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/023865d2-d6a9-4b43-a4e3-c1bb0da17c5c","type":"EvidenceLine","dc:description":"The evidence for autoimmunity is correlative with Th17 production and is not actually shown in the paper, thus, I am downgrading the score.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0bbbae3-d443-4619-8870-11e761a853ee","type":"Finding","dc:description":"Groups have shown that Stat3 is important for the development of the T helper 17 subset of CD4 T cells. TH17 cells are commonly associated with autoimmunity. Thus, this relationship between Stat3 and increased Th17 in patients with autoimmunity may be causal.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26343524","rdfs:label":"th17 in Stat3 GOF patients","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.25},{"id":"https://genegraph.clinicalgenome.org/r/47daba8d-d94b-4efc-ac42-28d9dd81e891_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb144980-afc0-4a3e-8bab-85c1afbee403","type":"EvidenceLine","dc:description":"I only gave 1 pt for this variant as the functional data showed increased Stat3 activity at baseline, but not after IL-6 stimulation. Modeling predicted this variant would increase Stat3 binding to DNA, but did not provide evidence for reduced function upon activation.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb144980-afc0-4a3e-8bab-85c1afbee403_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant was transfected into HEK293 cells with luciferase based reporter and activity was measured by dual luciferase activity. This variant demonstrated increased Stat3 activity at baseline and reduced Stat3 activity after IL-6 stimulation compared to WT. However, the functional response of this variant to known LOF variants was still significantly increased.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/cb144980-afc0-4a3e-8bab-85c1afbee403_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25038750","allele":{"id":"https://genegraph.clinicalgenome.org/r/96c91239-d45f-48a3-b529-70d53503e56c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1938C>G (p.Asn646Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA170587"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/427d017e-7e52-4455-838f-21e48f973950","type":"EvidenceLine","dc:description":"This variant was found to be de novo in an affected individual with strong functional data. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/427d017e-7e52-4455-838f-21e48f973950_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant was transfected into HEK293 cells with luciferase based reporter and activity was measured by dual luciferase activity. This variant demonstrated increased Stat3 activity at baseline and after IL-6 stimulation when compared to Wt.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/427d017e-7e52-4455-838f-21e48f973950_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25038750","allele":{"id":"https://genegraph.clinicalgenome.org/r/d980fbd2-d37e-43e7-a237-933cf68a69ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1175A>G (p.Lys392Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA170585"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4b230475-607c-49e8-bd4e-71f71d4d1325","type":"EvidenceLine","dc:description":"This individual demonstrated a slightly different phenotype than most patients, but still showed autoimmunity at a young age. This de novo variant was functionally shown to increase the activity of Stat3. Taken together, I upgraded the scoring to 1.5 pts.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b230475-607c-49e8-bd4e-71f71d4d1325_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant was transfected into HEK293 cells with luciferase based reporter and activity was measured by dual luciferase activity. This variant demonstrated increased Stat3 activity at baseline and after IL-6 stimulation when compared to Wt.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4b230475-607c-49e8-bd4e-71f71d4d1325_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25038750","allele":{"id":"https://genegraph.clinicalgenome.org/r/ecf46ceb-1664-4f74-b95b-abc87b8c6124","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1974G>C (p.Lys658Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA170590"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/715852c7-30ff-40e9-882d-bd603770cf3d","type":"EvidenceLine","dc:description":"This de novo variant is demonstrated to cause STAT3 functional alterations. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/715852c7-30ff-40e9-882d-bd603770cf3d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Stat3 activity driven luciferase assay demonstrated gain of function of this variant at baseline and following IL-6 and IFN-alpha stimulation when compared to WT control.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/715852c7-30ff-40e9-882d-bd603770cf3d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7f7c1cd-0be9-4ce6-b83f-2eca04b3d961","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1032G>C (p.Gln344His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357936"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/87368f61-5d60-4e87-9c51-14afa66b5177","type":"EvidenceLine","dc:description":"Increased score for this de novo variant due to the strong functional data.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87368f61-5d60-4e87-9c51-14afa66b5177_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Stat3 activity driven luciferase assay demonstrated gain of function of this variant at baseline and following IL-6 and IFN-alpha stimulation.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/87368f61-5d60-4e87-9c51-14afa66b5177_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","allele":{"id":"https://genegraph.clinicalgenome.org/r/0c52c841-fb9b-4399-9ad7-bc393ebd7cb5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.454C>T (p.Arg152Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357942"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/58f40dfd-6b1e-40a0-8e47-12261c00300e","type":"EvidenceLine","dc:description":"Upgraded to 1.0 due to strong functional data supporting gene disease assertion.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58f40dfd-6b1e-40a0-8e47-12261c00300e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant was functionally tested using a STAT3 responsive luciferase assay, demonstrating increased Stat3 activity upon treatment with IL-6. Measurement of pSTAT3 levels after IL-6 induced activation also showed increased Stat3 activity compared to WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/58f40dfd-6b1e-40a0-8e47-12261c00300e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25349174","allele":{"id":"https://genegraph.clinicalgenome.org/r/6f4ac3a1-4b68-4991-8ee5-8813410b4444","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1181T>C (p.Met394Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA399588925"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/81ce00b9-1e59-47e3-a4bd-93c8028ed498","type":"EvidenceLine","dc:description":"Kept score at 1.0 due to de novo single variant in an AD disease. Did not increase scoring because of the mixed functional study showing increased Stat3 response to IFN-alpha, but not to IL-6","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81ce00b9-1e59-47e3-a4bd-93c8028ed498_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A Stat3 activity luciferase reporter assay demonstrates this variant increases functional activity of Stat3 at baseline and after IFN-alpha stimulation. Stimulation with IL-6 does not cause a significant increase in Stat3 activity.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/81ce00b9-1e59-47e3-a4bd-93c8028ed498_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","allele":{"id":"https://genegraph.clinicalgenome.org/r/e02c9d7f-7180-462e-b1e0-ec00cc44f5e8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1261G>A (p.Gly421Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357947"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/36c733b7-34f8-4d3a-8b77-51b8ba9cb640","type":"EvidenceLine","dc:description":"This is a single de novo mutation with strong functional data in an autosomal dominant disease. Therefore I have upgraded the score from 1 to 1.5","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/36c733b7-34f8-4d3a-8b77-51b8ba9cb640_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant was transfected into HEK293 cells with luciferase based reporter and activity was measured by dual luciferase activity. This variant demonstrated increased Stat3 activity at baseline and after IL-6 stimulation when compared to Wt.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/36c733b7-34f8-4d3a-8b77-51b8ba9cb640_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25038750","allele":{"id":"https://genegraph.clinicalgenome.org/r/5d154030-8c88-41c3-8946-27628ced289e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.2147C>T (p.Thr716Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357939"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b774daec-7d0f-4644-b301-e423798dd339","type":"EvidenceLine","dc:description":"Did not increase this de novo variant as IL-6 induced Stat3 activity showed no difference compared to WT, as should been seen in this experimental system.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b774daec-7d0f-4644-b301-e423798dd339_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Stat3 activity driven luciferase assay demonstrated gain of function of this variant at baseline and following IFN-alpha stimulation when compared to WT control. IL-6 did not increase Stat3 activity beyond WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b774daec-7d0f-4644-b301-e423798dd339_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","allele":{"id":"https://genegraph.clinicalgenome.org/r/1cb99d61-923a-4223-85d4-15d8a6ee74ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1988C>T (p.Thr663Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357959"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/dc7f36b6-b79f-441c-8ead-2794baa6f098","type":"EvidenceLine","dc:description":"This variant was found to be paternally inherited and is not de novo. Interestingly, the father is unaffected from disease.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc7f36b6-b79f-441c-8ead-2794baa6f098_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Stat3 activity driven luciferase assay demonstrated gain of function of this variant after IL-6 and IFN-alpha stimulation. Functional Stat3 differences were not appreciated for this variant at baseline.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/dc7f36b6-b79f-441c-8ead-2794baa6f098_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25359994","allele":{"id":"https://genegraph.clinicalgenome.org/r/9c3a0285-a58b-42bf-83d8-cd3a34006710","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_139276.3(STAT3):c.1057G>T (p.Val353Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357951"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":3991,"specifiedBy":"GeneValidityCriteria8","strengthScore":16.25,"subject":{"id":"https://genegraph.clinicalgenome.org/r/l3UHZvpZlNg","type":"GeneValidityProposition","disease":"obo:MONDO_0014414","gene":"hgnc:11364","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_47daba8d-d94b-4efc-ac42-28d9dd81e891-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}